StockNews.com upgraded shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) from a hold rating to a buy rating in a research report released on Monday morning. Other analysts also recently issued reports about the company. Benchmark reissued a buy rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on […]